Eli Health’s Hormometer is a pioneering at-home hormone monitoring system that analyzes cortisol and progesterone levels in saliva, offering real-time health insights. Launched at CES 2025, it transforms smartphones into portable hormone analyzers using advanced AI and a simple 60-second saliva test. The technology, developed over five years with over a dozen patent-pending inventions, achieves 97% correlation for cortisol and 94% for progesterone compared to FDA-approved lab methods, ensuring lab-grade accuracy.
The Hormometer provides continuous tracking, unlike traditional lab tests that are costly, time-intensive, and offer only snapshots. It syncs with devices like Apple Health, Oura, or Fitbit, aligning cortisol peaks with heart-rate spikes for stress insights. Users receive personalized recommendations via the Eli app to manage stress, sleep, fertility, and perimenopause symptoms. Progesterone monitoring supports ovulation confirmation and menopause transitions, with safe use during pregnancy or breastfeeding when interpreted with professional guidance.
Founded in 2019 by Marina Pavlovic Rivas and Thomas Cortina, Eli Health aims to make hormone monitoring as routine as brushing teeth. Based in Montreal, the company leverages innovations in nanotechnology, microfluidics, chemistry, AI, and endocrinology. It produces tests in-house, ensuring affordability, with subscription plans starting at $8 per test for a 12-month commitment.
Eli’s mission is to empower users, particularly women, with data-driven health decisions from puberty to post-menopause. Cortisol impacts metabolism, sleep, and mental well-being, while progesterone influences fertility and hormonal balance. The system is not a diagnostic tool but supports lifestyle adjustments, complementing professional medical advice. Currently in limited beta, users can join a waitlist for early access. Eli Health, backed by $3.6 million in seed funding, is expanding to include testosterone and estradiol tests, advancing precision medicine.
Eli Health’s Hormometer began its beta access phase in the United States and Canada in January 2025, with limited spots available for early adopters. A full public release is planned for later in 2025, though an exact date has not been specified. Interested users can join the waitlist on Eli Health’s website to secure early access.